Compare Koninklijke Philips NV (PHG) vs SELLAS Life Sciences Group Inc. Common Stock (SLS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Koninklijke Philips NV vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Koninklijke Philips NV trades at $24.38 (market cap $23.68B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.27 (market cap $2.28B). The key difference: Koninklijke Philips NV is far larger — about 10.4× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Koninklijke Philips NV pays a 4.21% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| PHG | SLS | |
|---|---|---|
Market Cap | $23.68B | $2.28B |
Volume | 1,443,075 | 3,128,960 |
Sector | Health | Health |
52-Week High | $32.91 | $15.46 |
52-Week Low | $23.81 | $1.39 |
Typical Hold Time | 84 Days | — |
Enterprise Value | $30.07B | $2.15B |
Dividend Yield | 4.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PHG trades at $24.30, up 0.62% with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with net income turning positive to $895M in 2025 after previous losses, supported by strong operational cash flow of $1.17B. Analyst consensus leans Hold (63.64%) while institutional activity remains active with recent purchases by Bank of America and Arrowstreet Capital.
The outlook balances recovery momentum against technical weakness. Investment opportunity lies in continued earnings improvement and new product launches, while risks include competitive pressures and the bearish technical trend. Debt levels remain manageable with debt-to-asset ratio at 25.44% as of 2025.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →
